QU
QURE.US Uniqure NV
- Market cap
- USD 1.46B
- P/E
- -
- P/B
- 5.21x
- ROE
- -88.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QURE.US undervalued?
Graham numberThe Graham number of Uniqure NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Uniqure NV fundamental analysis
No fundamental analysis for Uniqure NV yet.
Uniqure NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the …
Full company profileUniqure NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Uniqure NV annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25.1M | 13.1M | 11.3M | 7.28M | 37.5M | 524M | 106M | 15.8M | 27.1M | 16.1M | 19.5M |
| Gross Profit | 25.1M | -54.3M | -61.8M | 7.28M | -84.9M | 499M | 103M | 2.22M | 8.79M | 14.4M | 5.00M |
| Operating Income | -71.9M | -72.0M | -88.2M | -121M | -125M | 311M | -143M | -283M | -184M | -188M | -204M |
| EBITDA | -65.9M | -69.7M | -74.0M | -114M | -127M | 319M | -108M | -253M | -161M | -117M | -195M |
| Net Income | -73.4M | -80.4M | -83.3M | -124M | -125M | 330M | -127M | -308M | -240M | -199M | -261M |
| EPS | -2.93 | -2.98 | -2.34 | -3.11 | -2.81 | 7.04 | -2.71 | -6.47 | -4.92 | -3.46 | -3.74 |
| Balance Sheet | |||||||||||
| Total Assets | 190M | 209M | 274M | 449M | 340M | 809M | 705M | 832M | 557M | 825M | 941M |
| Total Liabilities | 127M | 119M | 94.3M | 126M | 96.5M | 213M | 229M | 624M | 563M | 626M | 646M |
| Shareholders' Equity | 63.6M | 89.9M | 180M | 323M | 244M | 596M | 476M | 208M | -6.75M | 199M | 295M |
| Cash & Short-term Investments | 132M | 159M | 235M | 378M | 245M | 556M | 353M | 618M | 368M | 623M | 668M |
| Total Debt | 20.2M | 21.6M | 43.5M | 73.1M | 71.5M | 136M | 143M | 138M | 66.1M | 537M | 62.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -72.2M | -64.3M | -76.0M | -98.7M | -135M | 288M | -145M | -146M | -183M | -178M | -153M |
| Capital Expenditure | 17.2M | 5.58M | 4.25M | 6.65M | 9.48M | 17.4M | 17.7M | 7.15M | 3.37M | 439K | 831K |
| Free Cash Flow | -89.4M | -69.9M | -80.3M | -105M | -144M | 271M | -163M | -153M | -186M | -178M | -154M |
| Ratios | |||||||||||
| ROE | -115.3% | -89.4% | -46.4% | -38.4% | -51.3% | 55.3% | -26.6% | -148.5% | - | -100.0% | -88.6% |
| ROA | -38.6% | -38.5% | -30.4% | -27.7% | -36.7% | 40.7% | -18.0% | -37.1% | -43.0% | -24.1% | -27.8% |
| Net Profit Margin | -292.3% | -613.3% | -738.2% | -1,705.8% | -333.3% | 62.9% | -119.1% | -1,947.1% | -883.4% | -1,236.0% | -1,341.3% |
| Debt to Equity | 0.32x | 0.24x | 0.24x | 0.23x | 0.29x | 0.23x | 0.30x | 0.67x | - | 2.70x | 0.21x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Uniqure NV dividends
Uniqure NV has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Jan 31, 2014.
Who owns Uniqure NV
- Insiders 1.26%
- Institutions 88.51%
- Public & others 10.23%
- Shares outstanding 70.1M
- Free float 58.3M
Top funds holding QURE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.18M | 3.11% | +2.68% | Oct 2026 |
| JPMorgan Growth Advantage A | 1.71M | 2.44% | -2.20% | Sep 2026 |
| JPMorgan Mid Cap Growth I | 1.21M | 1.72% | -1.57% | Sep 2026 |
| abrdn Healthcare Investors | 922K | 1.32% | +123.87% | Oct 2026 |
| Worldwide Healthcare Ord | 746K | 1.06% | 0.00% | Jul 2026 |
| iShares Biotechnology ETF | 502K | 0.72% | -0.19% | Oct 2026 |
| abrdn World Healthcare | 426K | 0.61% | +63.99% | Sep 2026 |
| JPMorgan Small Cap Growth A | 425K | 0.61% | -15.12% | Sep 2026 |
| JPMorgan Active Growth ETF | 414K | 0.59% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 389K | 0.56% | 0.00% | Aug 2026 |
| abrdn Life Sciences Investors | 386K | 0.55% | +6.73% | Oct 2026 |
| abrdn Healthcare Opportunities | 385K | 0.55% | +228.84% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 367K | 0.52% | +0.24% | Oct 2026 |
| PGIM Jennison Health Sciences Z | 337K | 0.48% | 0.00% | Sep 2026 |
| JNL/JPMorgan MidCap Growth A | 326K | 0.46% | +24.29% | Sep 2026 |
| Fidelity Extended Market Index | 319K | 0.45% | -3.90% | Sep 2026 |
| Biotech Growth Ord | 276K | 0.39% | 0.00% | Jul 2026 |
| Fidelity Advisor Biotechnology I | 248K | 0.35% | +66.49% | Sep 2026 |
| Fidelity Select Pharmaceuticals Port | 227K | 0.32% | +181.61% | Sep 2026 |
| Nomura Healthcare Fund Class I | 218K | 0.31% | 0.00% | Sep 2026 |
Top institutions holding QURE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| venBio Select Advisor LLC | 6.73M | 9.61% | +12.89% | Jun 2026 |
| JPMorgan Chase & Co | 4.87M | 6.95% | +71.55% | Jun 2026 |
| RTW INVESTMENTS, LLC | 3.94M | 5.63% | +52.40% | Jun 2026 |
| State Street Corp | 2.90M | 4.15% | +28.46% | Jun 2026 |
| Aberdeen Group PLC | 1.92M | 2.73% | -32.75% | Sep 2026 |
| BlackRock Inc | 1.88M | 2.68% | +8.31% | Jun 2026 |
| Orbimed Advisors LLC | 1.81M | 2.58% | -15.39% | Jun 2026 |
| Jane Street Group LLC | 1.61M | 2.30% | +153.22% | Jun 2026 |
| Jennison Associates LLC | 1.56M | 2.23% | +26.55% | Jun 2026 |
| Boxer Capital Management, LLC | 1.50M | 2.15% | +127.08% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.48M | 2.11% | +16.84% | Jun 2026 |
| Two Sigma Investments LLC | 1.46M | 2.09% | -45.36% | Jun 2026 |
| FMR Inc | 1.27M | 1.81% | -27.17% | Jun 2026 |
| Mak Capital One LLC | 1.23M | 1.76% | +179.25% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.23M | 1.75% | -10.47% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.07M | 1.52% | +191.34% | Jun 2026 |
| Assenagon Asset Management SA | 1.03M | 1.47% | +599.88% | Jun 2026 |
| Vestal Point Capital LP | 935K | 1.33% | +160.45% | Jun 2026 |
| Maverick Capital Ltd | 925K | 1.32% | +32.64% | Jun 2026 |
| Nantahala Capital Management, LLC | 911K | 1.30% | +284.40% | Jun 2026 |
Uniqure NV company profile
- Company name
- Uniqure NV
- Ticker
- QURE.US
- ISIN
- NL0010696654
- Exchange
- USA Stocks
- Listed since
- Jun 20, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 221
- Fiscal year end
- December
- Address
- Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
- Phone
- 31 20 240 6000
- Website
- uniqure.com
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Uniqure NV management
10- Mr. Matthew Craig Kapusta CPACEO & Executive Director · born 1972
- Mr. Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site · born 1973
- Dr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance Officer and Corporate Secretary · born 1962
- Dr. Walid Abi-Saab M.D.Chief Medical Officer · born 1965
- Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Amin Abujoub Ph.D.Chief Technical Operations Officer
- Mr. Richard Porter Ph.D.Chief Business & Scientific Officer · born 1968
- Ms. Chiara Elizabeth RussoSenior Director of Investor Relations
- Dr. Tamara Tugal Ph.D., MBABusiness Development Director
- Ms. Erin BoyerChief People & Culture Officer